Molecular Pharmacology

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

Retrieved on: 
Martedì, Febbraio 27, 2024
MSK, University, Research, DKFZ, Quality of life, Sidney Kimmel, Radiology, National academy, ICAD, Faculty, Molecular Pharmacology, Translation, Trustee, Johns Hopkins University, NAM, Biomedical sciences, Book, Medical device

Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.

Key Points: 
  • Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.
  • Dr. Hricak is a member of the National Academy of Medicine and received the David Rall Medal, the NAM award for distinguished leadership.
  • The hallmark of her academic career has been developing, translating, and disseminating new diagnostic imaging techniques, primarily for genitourinary cancers.
  • “We are thrilled to welcome Dr. Hricak to the iCAD Board of Directors,” said Dana Brown, President, CEO, and Chairman of the Board.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Retrieved on: 
Domenica, Dicembre 10, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecular Pharmacology, Fever, Associate, Azacitidine, Hypotension, Safety, CCR, Spacecraft, Pneumonia, ASH, University, Cytopenia, Disease, Cellular, Constipation, Fatigue, Mortality, Penile ultrasonography, Patient, IMGN, DNA, MRD, Medical Affairs Bureau, Pharmacokinetics, Peripheral edema, Flow cytometry, Capillary leak syndrome, MD, Diarrhea, Cancer, Nausea, Survival, Drug resistance, Transplant, AML, Apoptosis, MD Anderson Cancer Center, Society, ImmunoGen, Hypokalemia, Hypophosphatemia, Venetoclax, Rare-earth element, Pharmaceutical industry, Birth control, Vaccine, Medicinal plants, Research

These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Key Points: 
  • These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
  • “The MRD negativity rates, which are indicative of a deep remission, are particularly promising in the treated patient population.
  • Response rates and MRD negativity were numerically comparable between cohorts 1 and 2, despite differences in the venetoclax schedule.
  • We look forward to continuing to expand our cohort of newly diagnosed unfit patients to inform the development path for pivekimab in AML.”
    ImmunoGen is also presenting two preclinical posters at ASH.

Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses

Retrieved on: 
Martedì, Settembre 12, 2023
Human, FNLCR, Nature Portfolio, T cell, Leidos, Frederick National Laboratory for Cancer Research, Neoplasm, Cancer, Lung cancer, Molecular Pharmacology, Literature, Scientific Reports, Mouse, Growth, Therapy, Tumor microenvironment, Pharmaceutical industry

The studies showed that oral treatment with IRX4647 in combination with an immune checkpoint inhibitor (anti-PD-L1) resulted in suppression of a typically checkpoint inhibitor treatment-resistant syngeneic lung cancer in mice.

Key Points: 
  • The studies showed that oral treatment with IRX4647 in combination with an immune checkpoint inhibitor (anti-PD-L1) resulted in suppression of a typically checkpoint inhibitor treatment-resistant syngeneic lung cancer in mice.
  • IRX4647 did not appreciably impact growth of the lung tumor cells in cultures, indicating that the compound alone is not directly toxic to lung cancer cells.
  • Studies in other syngeneic mouse cancer models implicated the tumor microenvironment in these anti-cancer effects since T cell depletion antagonized those effects.
  • Dr. Dmitrovsky stated, “These results reveal an approach to potentially improve treatment of cancers in humans using combinations of retinoic acid nuclear receptor gamma agonists with checkpoint inhibitors.

Ipsos: Appointment of Dr Bonnie Bain as Global Head of Healthcare

Retrieved on: 
Lunedì, Settembre 11, 2023
Krannert School of Management, University, GlobalData, Doctor of Philosophy, Ipsos, Health care, Molecular Pharmacology, Decision, Molecular biology, Purdue University, Ethnic group, Employee resource group, Purdue University College of Pharmacy, Pharmacology, Epidemiology, Pharmaceutical industry, Biochemistry

Paris, September 11, 2023 - I am pleased to announce that Dr Bonnie Bain, PhD has been appointed Global Head of Healthcare and will join us on 11th September.

Key Points: 
  • Paris, September 11, 2023 - I am pleased to announce that Dr Bonnie Bain, PhD has been appointed Global Head of Healthcare and will join us on 11th September.
  • Bonnie brings a wealth of valuable experience and expertise to the role and a wonderfully positive, inclusive approach.
  • Prior to joining Ipsos, she was Global Head of Pharma and Executive VP of Healthcare Operations & Strategy at GlobalData Plc.
  • Bonnie commented: “I am very excited to be taking on the role of Global Head of Healthcare and building on the success of the teams.

The Inner Circle Acknowledges, Darren N. Seril, MD, Ph.D., as a Top Pinnacle Provider for his contributions to the medical field

Retrieved on: 
Lunedì, Aprile 17, 2023
Medical school, RWJBarnabas Health, Crohn's & Colitis Foundation, Gastroenterology, Doctor of Philosophy, American Gastroenterological Association, Pancreas, Human, Molecular Pharmacology, Esophagus, Mentorship, Disorder, Inner circle, Stomach, Colon, Rutgers University, Inflammatory bowel disease, Crohn's disease, Cleveland, Robert Wood Johnson University Hospital, Medical degree, Robert Wood Johnson Medical School, Thomas Jefferson University Hospital, Cleveland Clinic, Liver, Patient, American College of Gastroenterology, American College, Pharmacology, Nursing, MD, Biology, Medicine

PLAINFIELD, N.J., April 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Darren N. Seril, MD, Ph.D., is acknowledged as a Top Pinnacle Provider for his contributions to the medical field.

Key Points: 
  • PLAINFIELD, N.J., April 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Darren N. Seril, MD, Ph.D., is acknowledged as a Top Pinnacle Provider for his contributions to the medical field.
  • Dr. Seril earned a Bachelor of Science degree in Biology and a Ph.D. in Molecular Pharmacology from Rutgers University.
  • He received a Medical Degree from the Robert Wood Johnson School of Medicine and completed his internal medicine residency at Thomas Jefferson University Hospital in Philadelphia, PA.
  • He asserts that he has advanced training in this field and also teaches fellowship students who are training in this specialty.

Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

Retrieved on: 
Giovedì, Marzo 30, 2023
Biotechnology, Pharmaceutical, Health, Therapy, Biopharmaceutical, Molecular Pharmacology, Translation, Science, Stanford University School of Medicine, Growth, NYSE, Management, Medical device

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the Company has hired G2G Ventures (G2G) as Executive Consultants to provide executive team support for Navidea’s aggressive growth plans.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the Company has hired G2G Ventures (G2G) as Executive Consultants to provide executive team support for Navidea’s aggressive growth plans.
  • Separately, Michael Rosol, Ph.D., has stepped down as Chief Medical Officer for the Company.
  • "We are incredibly excited to work with this unique organization,” Dr. Jason Myers, Owner and Founder of G2G Ventures, said.
  • The role of Chief Medical Officer will be assumed by existing leadership with coordinated support from G2G Ventures.

Boehringer Ingelheim announces appointments to Board of Managing Directors

Retrieved on: 
Martedì, Dicembre 20, 2022
Pharmaceutical, Health, Veterinary, Shareholder, Business development, Pharmacology, Molecular Pharmacology, Innovation, Medicinal chemistry, Marketing, Business administration, Boehringer Ingelheim, Innovation Unit, Doctor of Philosophy, Shashank, Executive Office of the President of the United States, Management, Research

Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors.

Key Points: 
  • Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors.
  • Paola joined Boehringer Ingelheim in 2007 and is currently Global Head of Therapeutic Areas in the Human Pharma Business Unit.
  • Shashank joined Boehringer Ingelheim in 2012 and is currently Country Managing Director Japan.
  • The Board is excited to welcome Paola and Shashank to the team later next year.”
    The appointment to the Board of Managing Directors will be effective July 1, 2023 for Paola Casarosa and September 1, 2023 for Shashank Deshpande.

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

Retrieved on: 
Giovedì, Gennaio 6, 2022
FXR, Safety, COVID-19, Drug discovery, University, VAP-1, University of California, San Diego Performance-Based Skills Assessment, American Journal, Doctor of Philosophy, Therapy, California Polytechnic State University, Chemistry, Research, Company, Patient, Fatty liver disease, Risk, Molecular Pharmacology, Annual report, Merck & Co., Editorial board, Disease, Ageing, Pharmacology, GLOBE, Terminology, Takeda Pharmaceutical Company, Stanford University, THR, Pharmaceutical industry, Medical device, Tern

Terns also announced the promotion of Diana Chung to senior vice president, chief development officer.

Key Points: 
  • Terns also announced the promotion of Diana Chung to senior vice president, chief development officer.
  • Both Dr. Jasper and Ms. Chung will report to Erin Quirk, M.D., president, head of research and development and chief medical officer.
  • Attracting top talent and developing our management team is essential to our success, said Senthil Sundaram, chief executive officer at Terns.
  • Ms. Chung was previously senior vice president, clinical development and operations at Terns.

Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Mercoledì, Dicembre 1, 2021
NHP, Security (finance), Pharmacology, Half-life, Private Securities Litigation Reform Act, Company, Plasma, Cancer, Primate, Tumor microenvironment, Inflammation, SEC, NK, U.S. Securities and Exchange Commission, Therapy, Lymphoid neoplasms with plasmablastic differentiation, COVID-19, Cytokine release syndrome, Cytokine, EST, Drug resistance, Neoplasm, GLOBE, Molecular Pharmacology, Terminology, American Society of Hematology, Society, Syngenic, Lymphatic system, Vaccine, Pharmaceutical industry, Medical imaging

These data will be presented in a poster presentation during the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14, 2021.

Key Points: 
  • These data will be presented in a poster presentation during the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14, 2021.
  • WTX-330 and WTX-613 are systemically delivered, conditionally activated IL-12 and IFN INDUKINE molecules, respectively, for the potential treatment of solid tumors.
  • Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.
  • Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment.

Labroots Announces 12th Consecutive Year Hosting its Clinical Diagnostics & Research Virtual Event, scheduled on November 10th, 2021

Retrieved on: 
Giovedì, Novembre 4, 2021
Molecular Pharmacology, Science, Program, SPME, Research, UTI, Nicolaus Copernicus University in Toruń, Technology, Biotechnology, PCR, Professor, University, Industry, United States, North East New Territories New Development Areas Planning, Health equity, Biomedical Research, Machine learning, Associate professor, University of Waterloo, Canada Research Chair, Severe acute respiratory syndrome coronavirus 2, Medicine, Intelligence, Precision medicine, Social media, Learning, Social, Medical applications of radio frequency, AI, Environment, Artificial intelligence, News, Development, Risk, Health, Department, Influenza and Other Respiratory Viruses, Solid-phase microextraction, LC-MS/MS, Medical device, Online shopping

YORBA LINDA, Calif., Nov. 4, 2021 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its Clinical Diagnostics & Research free online event, marking the 12th year!

Key Points: 
  • YORBA LINDA, Calif., Nov. 4, 2021 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its Clinical Diagnostics & Research free online event, marking the 12th year!
  • Clinical Diagnostics & Research 2021 provides a complete educational virtual venue to advance the science of diagnostics and improve the practice of medicine.
  • Viewers will understand the potential of the SPME technology in biomedical research.
  • Labroots, an approved provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.